Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: Effect of metformin administration

Daniela Manzella, Rodolfo Grella, Katherine Esposito, Dario Giugliano, Mario Barbagallo, Giuseppe Paolisso

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: Hyperinsulinemia/insulin resistance and elevated plasma free fatty acids (FFA) levels are involved in the hypertension and cardiac sympathetic overactivity. Metformin improves insulin action and lower plasma FFA concentrations. We investigate the possible effect of metformin on arterial blood pressure (BP) and cardiac sympathetic nervous system. Methods: One hundred twenty overweight type 2 diabetic patients were treated by placebo (n = 60) + diet or metformin (850 mg twice daily) (n = 60) + diet for 4 months, to evaluate the effect of metformin treatment on the cardiac autonomic nervous system. Insulin resistance was measured by the Homeostasis Model Assessment (HOMA) index. Heart rate variability (HRV) assessed cardiac sympathovagal balance. Results: Metformin treatment, but not placebo treatment, was associated with a decrease in fasting plasma glucose (P <.05), insulin (P <.05), triglyceride (P <.05), and FFA (P <.03) concentrations and HOMA index (P <.03). Metformin treatment was also associated with a significant improvement in cardiac sympathovagal balance but not in mean arterial BP. Furthermore, in a multivariate analysis, delta change in sympathovagal balance index (LF/HF ratio) were associated with delta change in plasma FFA concentrations and HOMA index independently of gender and delta change in plasma triglyceride and HbA1c concentrations. Conclusions: Our study demonstrated that metformin treatment might be useful for improving cardiac sympathovagal balance in obese type 2 diabetic patients.

Original languageEnglish
Pages (from-to)223-227
Number of pages5
JournalAmerican Journal of Hypertension
Volume17
Issue number3
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Metformin
Autonomic Nervous System
Blood Pressure
Nonesterified Fatty Acids
Arterial Pressure
Homeostasis
Insulin Resistance
Triglycerides
Placebos
Insulin
Diet
Therapeutics
Sympathetic Nervous System
Hyperinsulinism
Fasting
Multivariate Analysis
Heart Rate
Hypertension
Glucose

Keywords

  • Blood pressure
  • Free fatty acids
  • Heart rate variability
  • Insulin resistance
  • Metformin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients : Effect of metformin administration. / Manzella, Daniela; Grella, Rodolfo; Esposito, Katherine; Giugliano, Dario; Barbagallo, Mario; Paolisso, Giuseppe.

In: American Journal of Hypertension, Vol. 17, No. 3, 03.2004, p. 223-227.

Research output: Contribution to journalArticle

Manzella, Daniela ; Grella, Rodolfo ; Esposito, Katherine ; Giugliano, Dario ; Barbagallo, Mario ; Paolisso, Giuseppe. / Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients : Effect of metformin administration. In: American Journal of Hypertension. 2004 ; Vol. 17, No. 3. pp. 223-227.
@article{3cc34f4869ba4e70863f9890dd9a6d63,
title = "Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: Effect of metformin administration",
abstract = "Background: Hyperinsulinemia/insulin resistance and elevated plasma free fatty acids (FFA) levels are involved in the hypertension and cardiac sympathetic overactivity. Metformin improves insulin action and lower plasma FFA concentrations. We investigate the possible effect of metformin on arterial blood pressure (BP) and cardiac sympathetic nervous system. Methods: One hundred twenty overweight type 2 diabetic patients were treated by placebo (n = 60) + diet or metformin (850 mg twice daily) (n = 60) + diet for 4 months, to evaluate the effect of metformin treatment on the cardiac autonomic nervous system. Insulin resistance was measured by the Homeostasis Model Assessment (HOMA) index. Heart rate variability (HRV) assessed cardiac sympathovagal balance. Results: Metformin treatment, but not placebo treatment, was associated with a decrease in fasting plasma glucose (P <.05), insulin (P <.05), triglyceride (P <.05), and FFA (P <.03) concentrations and HOMA index (P <.03). Metformin treatment was also associated with a significant improvement in cardiac sympathovagal balance but not in mean arterial BP. Furthermore, in a multivariate analysis, delta change in sympathovagal balance index (LF/HF ratio) were associated with delta change in plasma FFA concentrations and HOMA index independently of gender and delta change in plasma triglyceride and HbA1c concentrations. Conclusions: Our study demonstrated that metformin treatment might be useful for improving cardiac sympathovagal balance in obese type 2 diabetic patients.",
keywords = "Blood pressure, Free fatty acids, Heart rate variability, Insulin resistance, Metformin",
author = "Daniela Manzella and Rodolfo Grella and Katherine Esposito and Dario Giugliano and Mario Barbagallo and Giuseppe Paolisso",
year = "2004",
month = "3",
doi = "10.1016/j.amjhyper.2003.11.006",
language = "English",
volume = "17",
pages = "223--227",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients

T2 - Effect of metformin administration

AU - Manzella, Daniela

AU - Grella, Rodolfo

AU - Esposito, Katherine

AU - Giugliano, Dario

AU - Barbagallo, Mario

AU - Paolisso, Giuseppe

PY - 2004/3

Y1 - 2004/3

N2 - Background: Hyperinsulinemia/insulin resistance and elevated plasma free fatty acids (FFA) levels are involved in the hypertension and cardiac sympathetic overactivity. Metformin improves insulin action and lower plasma FFA concentrations. We investigate the possible effect of metformin on arterial blood pressure (BP) and cardiac sympathetic nervous system. Methods: One hundred twenty overweight type 2 diabetic patients were treated by placebo (n = 60) + diet or metformin (850 mg twice daily) (n = 60) + diet for 4 months, to evaluate the effect of metformin treatment on the cardiac autonomic nervous system. Insulin resistance was measured by the Homeostasis Model Assessment (HOMA) index. Heart rate variability (HRV) assessed cardiac sympathovagal balance. Results: Metformin treatment, but not placebo treatment, was associated with a decrease in fasting plasma glucose (P <.05), insulin (P <.05), triglyceride (P <.05), and FFA (P <.03) concentrations and HOMA index (P <.03). Metformin treatment was also associated with a significant improvement in cardiac sympathovagal balance but not in mean arterial BP. Furthermore, in a multivariate analysis, delta change in sympathovagal balance index (LF/HF ratio) were associated with delta change in plasma FFA concentrations and HOMA index independently of gender and delta change in plasma triglyceride and HbA1c concentrations. Conclusions: Our study demonstrated that metformin treatment might be useful for improving cardiac sympathovagal balance in obese type 2 diabetic patients.

AB - Background: Hyperinsulinemia/insulin resistance and elevated plasma free fatty acids (FFA) levels are involved in the hypertension and cardiac sympathetic overactivity. Metformin improves insulin action and lower plasma FFA concentrations. We investigate the possible effect of metformin on arterial blood pressure (BP) and cardiac sympathetic nervous system. Methods: One hundred twenty overweight type 2 diabetic patients were treated by placebo (n = 60) + diet or metformin (850 mg twice daily) (n = 60) + diet for 4 months, to evaluate the effect of metformin treatment on the cardiac autonomic nervous system. Insulin resistance was measured by the Homeostasis Model Assessment (HOMA) index. Heart rate variability (HRV) assessed cardiac sympathovagal balance. Results: Metformin treatment, but not placebo treatment, was associated with a decrease in fasting plasma glucose (P <.05), insulin (P <.05), triglyceride (P <.05), and FFA (P <.03) concentrations and HOMA index (P <.03). Metformin treatment was also associated with a significant improvement in cardiac sympathovagal balance but not in mean arterial BP. Furthermore, in a multivariate analysis, delta change in sympathovagal balance index (LF/HF ratio) were associated with delta change in plasma FFA concentrations and HOMA index independently of gender and delta change in plasma triglyceride and HbA1c concentrations. Conclusions: Our study demonstrated that metformin treatment might be useful for improving cardiac sympathovagal balance in obese type 2 diabetic patients.

KW - Blood pressure

KW - Free fatty acids

KW - Heart rate variability

KW - Insulin resistance

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=1442299291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442299291&partnerID=8YFLogxK

U2 - 10.1016/j.amjhyper.2003.11.006

DO - 10.1016/j.amjhyper.2003.11.006

M3 - Article

C2 - 15001195

AN - SCOPUS:1442299291

VL - 17

SP - 223

EP - 227

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 3

ER -